244 related articles for article (PubMed ID: 32821381)
21. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties.
Warhurst DC; Steele JC; Adagu IS; Craig JC; Cullander C
J Antimicrob Chemother; 2003 Aug; 52(2):188-93. PubMed ID: 12837731
[TBL] [Abstract][Full Text] [Related]
22. Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19.
Adeel AA
Sudan J Paediatr; 2020; 20(1):4-9. PubMed ID: 32528194
[TBL] [Abstract][Full Text] [Related]
23. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.
Das S; Ramachandran AK; Birangal SR; Akbar S; Ahmed B; Joseph A
Med Drug Discov; 2021 Jun; 10():100085. PubMed ID: 33846702
[TBL] [Abstract][Full Text] [Related]
24. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.
Manivannan E; Karthikeyan C; Moorthy NSHN; Chaturvedi SC
Front Pharmacol; 2021; 12():584940. PubMed ID: 34025393
[TBL] [Abstract][Full Text] [Related]
25. Research Progress of Chloroquine and Hydroxychloroquine on the COVID-19 and Their Potential Risks in Clinic Use.
Chen Y; Shen T; Zhong L; Liu Z; Dong X; Huang T; Wang Q; Xiao H
Front Pharmacol; 2020; 11():1167. PubMed ID: 32848774
[TBL] [Abstract][Full Text] [Related]
26. Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis.
Tleyjeh IM; Kashour Z; AlDosary O; Riaz M; Tlayjeh H; Garbati MA; Tleyjeh R; Al-Mallah MH; Sohail MR; Gerberi D; Bin Abdulhak AA; Giudicessi JR; Ackerman MJ; Kashour T
Mayo Clin Proc Innov Qual Outcomes; 2021 Feb; 5(1):137-150. PubMed ID: 33163895
[TBL] [Abstract][Full Text] [Related]
27. Encapsulated hydroxychloroquine and chloroquine into cyclic oligosaccharides are the potential therapeutics for COVID-19: insights from first-principles calculations.
Roy A; Das R; Roy D; Saha S; Ghosh NN; Bhattacharyya S; Roy MN
J Mol Struct; 2022 Jan; 1247():131371. PubMed ID: 34462609
[TBL] [Abstract][Full Text] [Related]
28. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.
Tang W; Khalili L; Giles J; Gartshteyn Y; Kapoor T; Guo C; Chen T; Theodore D; Askanase A
Rheumatol Ther; 2021 Jun; 8(2):681-691. PubMed ID: 34028704
[TBL] [Abstract][Full Text] [Related]
29. A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients.
Askarian F; Firoozi Z; Ebadollahi-Natanzi A; Bahrami S; Rahimi HR
Toxicol Res; 2022 Apr; 38(2):137-148. PubMed ID: 34306523
[TBL] [Abstract][Full Text] [Related]
30. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.
Dauner DG; Dauner KN
J Am Pharm Assoc (2003); 2021; 61(3):293-298. PubMed ID: 33546986
[TBL] [Abstract][Full Text] [Related]
31. Chloroquine, hydroxychloroquine and COVID-19.
Erickson TB; Chai PR; Boyer EW
Toxicol Commun; 2020; 4(1):40-42. PubMed ID: 32457932
[TBL] [Abstract][Full Text] [Related]
32. Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.
Sinha M; Gupta A; Gupta S; Singh P; Pandit S; Chauhan SS; Parthasarathi R
Comput Biol Med; 2021 Mar; 130():104222. PubMed ID: 33535144
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis.
Landsteiner de Sampaio Amêndola I; Aires Pinheiro J; Póvoa P; Cés de Souza Dantas V; Serafim RB
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431342
[TBL] [Abstract][Full Text] [Related]
34. Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2.
Satarker S; Ahuja T; Banerjee M; E VB; Dogra S; Agarwal T; Nampoothiri M
Curr Pharmacol Rep; 2020; 6(5):203-211. PubMed ID: 32864299
[TBL] [Abstract][Full Text] [Related]
35. Vinpocetine protects against chloroquine-induced cardiotoxicity by mitigating oxidative stress.
Abdelmageed N; Twafik WA; Morad OA; Haridy M; Hassan R; Ahmed M; El-Zorba HY; El-Banna HA; Seddek AL; Ghallab A; Morad SAF
Arch Toxicol; 2023 Oct; 97(10):2763-2770. PubMed ID: 37401952
[TBL] [Abstract][Full Text] [Related]
36. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials.
Ebina-Shibuya R; Namkoong H; Horita N; Kato H; Hara Y; Kobayashi N; Kaneko T
J Thorac Dis; 2021 Jan; 13(1):202-212. PubMed ID: 33569200
[TBL] [Abstract][Full Text] [Related]
37. Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.
Verbaanderd C; Maes H; Schaaf MB; Sukhatme VP; Pantziarka P; Sukhatme V; Agostinis P; Bouche G
Ecancermedicalscience; 2017; 11():781. PubMed ID: 29225688
[TBL] [Abstract][Full Text] [Related]
38. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
Lin YC; Lin JF; Wen SI; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
Kaohsiung J Med Sci; 2017 May; 33(5):215-223. PubMed ID: 28433067
[TBL] [Abstract][Full Text] [Related]
39. Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review.
Gbinigie K; Frie K
BJGP Open; 2020; 4(2):. PubMed ID: 32265182
[TBL] [Abstract][Full Text] [Related]
40. Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?
Zhan X; Dowell S; Shen Y; Lee DL
Heliyon; 2020 Sep; 6(9):e04900. PubMed ID: 32935064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
